Related Experiment Videos
[Hematopoietic stem cell transplantation for malignant lymphoma]
1Department of Hematology and Chemotherapy, Aichi Cancer Center, Nagoya, Japan.
Gan to Kagaku Ryoho. Cancer & Chemotherapy
|September 29, 1999
Summary
Autologous peripheral blood stem cell transplantation (auto-PBSCT) offers curative therapy for malignant lymphoma. It is indicated for relapsed aggressive lymphomas and high-risk newly diagnosed cases.
Area of Science:
- Hematology
- Oncology
- Stem Cell Transplantation
Context:
- Autologous peripheral blood stem cell transplantation (auto-PBSCT) is a key curative treatment for malignant lymphoma.
- Patients with relapsed, chemo-sensitive aggressive lymphomas are primary candidates.
- Newly diagnosed aggressive lymphomas with high-risk prognostic factors also benefit.
Purpose:
- To review the clinical outcomes of auto-PBSCT in malignant lymphoma.
- To delineate the indications for auto-PBSCT in various lymphoma subtypes.
- To provide a comprehensive overview of hematopoietic stem cell transplantation in lymphoma management.
Summary:
- This paper reviews the efficacy and patient selection for autologous peripheral blood stem cell transplantation (auto-PBSCT) in malignant lymphoma.
- It highlights that auto-PBSCT is suitable for aggressive lymphomas that have relapsed but remain chemo-sensitive, as well as for newly diagnosed cases with poor prognostic indicators.
- The review also encompasses broader clinical results and indications for hematopoietic stem cell transplantation across different lymphoma types.
Impact:
- Provides evidence-based guidance for utilizing auto-PBSCT in lymphoma treatment.
- Aids clinicians in identifying appropriate candidates for this intensive therapy.
- Contributes to optimizing lymphoma management strategies through stem cell transplantation.